Bloedingsrisicoscores: waarde voor de klinische praktijk

Translated title of the contribution: The clinical value of bleeding risk stratification

Eva C.I. Woelders, Jasper J.P. Luijkx, Arnoud W.J. van 't Hof*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Prediction of bleeding risk in patients receiving antithrombotic treatment has been repeatedly attempted and resulted in multiple risk models. Risk stratification can be used to personalize antithrombotic treatment to reduce bleeding complications. Although these risk models are validated and incorporated in the current guidelines, the feasibility and effectivity in daily practice remains questionable. Personalized antithrombotic treatment may be complex due to the number of risk factors that should be considered. Furthermore, most risk scores show moderate predictive value when they are validated externally or for a different treatment indication. However, personalized treatment seems key to minimalize bleeding events and is therefore indicated in all patients receiving antithrombotics. To increase the effectivity, it is important to use the appropriate model for each treatment indication. Online tools and the implementation of risk scores in the electronic medical record could facilitate the use of these scores.
Translated title of the contributionThe clinical value of bleeding risk stratification
Original languageDutch
Article numberD7755
JournalNederlands Tijdschrift voor Geneeskunde
Volume167
Publication statusPublished - 28 Nov 2023

Keywords

  • Humans
  • Fibrinolytic Agents/adverse effects
  • Electronic Health Records
  • Risk Factors
  • Risk Assessment

Cite this